Vaughan Nelson Investment Management L.P. Has $16.40 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Vaughan Nelson Investment Management L.P. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 71.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,199 shares of the medical research company’s stock after selling 175,874 shares during the quarter. Vaughan Nelson Investment Management L.P.’s holdings in IQVIA were worth $16,398,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of IQV. 1832 Asset Management L.P. raised its stake in IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after acquiring an additional 376,595 shares in the last quarter. Renaissance Technologies LLC acquired a new position in IQVIA during the second quarter worth $70,610,000. Impax Asset Management Group plc raised its stake in IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after acquiring an additional 264,555 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after acquiring an additional 211,653 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its stake in IQVIA by 285.1% during the second quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock worth $56,783,000 after acquiring an additional 198,808 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 5.1 %

Shares of IQVIA stock opened at $192.68 on Monday. IQVIA Holdings Inc. has a 12-month low of $189.63 and a 12-month high of $261.73. The stock has a market cap of $34.97 billion, a P/E ratio of 25.29, a P/E/G ratio of 1.98 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The business’s 50 day moving average is $226.95 and its 200-day moving average is $228.24.

Wall Street Analyst Weigh In

Several analysts have recently commented on IQV shares. Barclays decreased their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Argus upgraded IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Truist Financial dropped their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Finally, The Goldman Sachs Group dropped their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $259.13.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.